2019, Number 1
<< Back Next >>
Acta Med 2019; 17 (1)
Reversible leukoencephalopathy due to the use of thermogenic dietary supplements
Chamberlin VO, Villasana RO, Mora CJ, Álvarez RM, Domínguez CLG
Language: Spanish
References: 13
Page: 47-50
PDF size: 195.28 Kb.
ABSTRACT
Introduction: Due to the increase of obesity in Western countries, the use of thermogenic supplements to achieve weight loss is very frequent; however, the safety profiles of many of these substances are unknown, and there are reports of toxicity that include brain manifestations such as leukoencephalopathy.
Clinical cases: Sixteen and 21-year-old patients, both with a BMI › 30 and a history of using dietary supplements with a thermogenic effect for three months and one month respectively. They arrived with intense and progressive fronto-occipital headache. The younger sister, in addition to the headache, presented convergent strabismus due to VI nerve paresis and papilledema. Both had a magnetic resonance compatible with leukoencephalopathy. The first was managed with immunoglobulin and prednisolone, being discharged asymptomatic.
Conclusions: Dietary supplements with a thermogenic effect used to control and lose weight, are a danger for users due to cardiovascular and neurological complications.
REFERENCES
Campbell BI, Zito G, Colquhoun R, Martinez N, Kendall K, Buchanan L et al. The effects of a single-dose thermogenic supplement on resting metabolic rate and hemodynamic variables in healthy females—a randomized, double-blind, placebo-controlled, cross-over trial. J Int Soc Sports Nutr. 2016; 31: 13:13.
Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS). La COFEPRIS alerta sobre el producto Thermatrim. URL: http://www.cofepris.gob. mx/Documents/NotasPrincipales/03122014.pdf.
Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996; 334 (8): 494-500.
Filley CM, Kleinschmidt-DeMasters BK. Toxic leukoencephalopathy. N Engl J Med. 2001; 345 (6): 425-432.
McKinney AM, Kieffer SA, Paylor RT, SantaCruz KS, Kendi A, Lucato L. Acute toxic leukoencephalopathy: potential for reversibility clinically and on MRI with diffusion-weighted and FLAIR imaging. AJR Am J Roentgenol. 2009; 193 (1): 192-206.
Mahdavi ZK, Narayan R, Mainali S, Greenberg BM et al. A Callosal catastrophe: toxic leukoencephalopathy associated with thermogenic weight loss supplement use. Neurocrit Care. 2018; 29 (3): 504-507. doi: 10.1007/s12028-017-0473-9.
Rimkus C de M, Andrade CS, Leite Cda C, McKinney AM, Lucato LT. Toxic leukoencephalopathies, including drug, medication, environmental, and radiation-induced encephalopathic syndromes. Semin Ultrasound CT MR. 2014; 35: 97-117.
Cartier RL, González LD, Harán DJ. Leucoencefalopatía tóxica fatal: tres casos asociados al consumo de pasta base de cocaína. Rev Med Chile. 2015; 143 (11): 1484-1489.
Legriel S, Pico F, Azoulay E. Understanding posterior reversible encephalopathy syndrome. En: Vincent JL. (eds) Annual update in intensive care and emergency medicine 2011. Vol. 1. Annual Update in Intensive Care and Emergency Medicine 2011. Berlin: Springer Heidelberg; 2011. http://www.springer.com/978-3-642-18080-4
Osuna MT, Querol L, Olivas-Chacón CI, Lejarreta-Andrés S, Robert J, Ailouti-Caballero N et al. Neuropatía desmielinizante y leucoencefalopatía tóxicas en pacientes que toman los productos adelgazantes Thermatrim® y Pura alegría®. Rev Neurol. 2015; 61: 527-528.
Olivas-Chacon CI, Treviño-Garcia M, Chua-Tuan JJ, Rodriguez-Cordero JM, Gil-Valadez AH, Akle N et al. Leukoencephalopathic changes on magnetic resonance imaging associated with a thermogenic dietary supplement (Thermatrim). Proc (Bayl Univ Med Cent). 2015; 28: 389-391.
Miyamoto Y, Torii T, Takada S, Ohno N, Saitoh Y, Nakamura K et al. Involvement of the Tyro3 receptor and its intracellular partner Fyn signaling in Schwann cell myelination. Mol Biol Cell. 2015; 26 (19): 3489-3503.
Takanashi J, Imamura A, Hayakawa F, Terada H. Differences in the time course of splenial and white matter lesions in clinically mild encephalitis/encephalopathy with a reversible splenial lesion (MERS). J Neurol Sci. 2010; 292 (1-2): 24-27.